olodaterol
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
Boehringer complaint ruled out by PMCPA
January 15, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, COPD, PMCPA, Striverdi, olodaterol
A complaint made by a pharmacist stating that the artwork image for Boehringer Ingelheim’s COPD drug Striverdi is misleading has …
Boehringer spends €100 million on inhaler
September 30, 2014Manufacturing and Production, Sales and Marketing Boehringer, Germany, Spiriva, Striverdi, inhaler, olodaterol, respimat
Boehringer Ingelheim is to spend more than €100 million at its Dortmund site in Germany in order to expand the …
Boehringer’s Striverdi gains FDA approval
August 1, 2014Sales and Marketing Advair, COPD, Pfizer, Spiriva, asthma, olodaterol
Boehringer Ingelheim’s new lung drug Striverdi has gained US approval for patients with chronic obstructive pulmonary disorder. Striverdi Respimat (olodaterol), …
Boehringer’s COPD drug passes hurdle
May 23, 2012Research and Development, Sales and Marketing Boehringer, COPD, Daxas, Relovair, Spiriva, olodaterol
Boehringer Ingelheim’s once-daily bronchodilator olodaterol has improved lung function versus placebo in a Phase II trial. The manufacturer wants the …
